479 related articles for article (PubMed ID: 33148626)
1. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
[TBL] [Abstract][Full Text] [Related]
2. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
3. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren HG; Nahi H; Wagner AK; Alici E
Cancer Immunol Immunother; 2023 May; 72(5):1153-1167. PubMed ID: 36355079
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
[TBL] [Abstract][Full Text] [Related]
5. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.
Shankar K; Capitini CM; Saha K
Stem Cell Res Ther; 2020 Jun; 11(1):234. PubMed ID: 32546200
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells: the next wave in cancer immunotherapy.
Chen X; Jiang L; Liu X
Front Immunol; 2022; 13():954804. PubMed ID: 35967421
[TBL] [Abstract][Full Text] [Related]
7. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
Bogomiakova ME; Sekretova EK; Anufrieva KS; Khabarova PO; Kazakova AN; Bobrovsky PA; Grigoryeva TV; Eremeev AV; Lebedeva OS; Bogomazova AN; Lagarkova MA
Stem Cell Res Ther; 2023 Apr; 14(1):77. PubMed ID: 37038186
[TBL] [Abstract][Full Text] [Related]
8. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.
Cichocki F; van der Stegen SJC; Miller JS
Blood; 2023 Feb; 141(8):846-855. PubMed ID: 36327161
[TBL] [Abstract][Full Text] [Related]
9. Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy.
Chang Y; Jin G; Luo W; Luo Q; Jung J; Hummel SN; Torregrosa-Allen S; Elzey BD; Low PS; Lian XL; Bao X
Bioact Mater; 2023 Sep; 27():168-180. PubMed ID: 37091063
[TBL] [Abstract][Full Text] [Related]
10. iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
Zhang Y; Shi Q; Wang P; Huang C; Tang S; Zhou M; Hu Q; Wu L; Liang D
MedComm (2020); 2024 May; 5(5):e553. PubMed ID: 38737469
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.
Maeoka R; Nakazawa T; Matsuda R; Morimoto T; Shida Y; Yamada S; Nishimura F; Nakamura M; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762486
[TBL] [Abstract][Full Text] [Related]
12. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy.
Quatrini L; Mariotti FR; Munari E; Tumino N; Vacca P; Moretta L
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33172030
[TBL] [Abstract][Full Text] [Related]
13. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.
Karagiannis P; Kim SI
Mol Cells; 2021 Aug; 44(8):541-548. PubMed ID: 34373366
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory receptors and checkpoints on NK cells: Implications for cancer immunotherapy.
Li L; Li A; Jin H; Li M; Jia Q
Pathol Res Pract; 2024 Jan; 253():155003. PubMed ID: 38042093
[TBL] [Abstract][Full Text] [Related]
15. Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer.
Kinoshita S; Ishii M; Ando J; Kimura T; Yamaguchi T; Harada S; Takahashi F; Nakashima K; Nakazawa Y; Yamazaki S; Ohshima K; Takahashi K; Nakauchi H; Ando M
Cancer Res Commun; 2024 Mar; 4(3):723-737. PubMed ID: 38380966
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V; Chhetri JB; Ali S; Roddie C
Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
[TBL] [Abstract][Full Text] [Related]
17. The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function.
Okumura M; Yokoyama Y; Yoshida T; Okada Y; Takizawa M; Ikeda O; Kambayashi T
Int Immunopharmacol; 2023 Dec; 125(Pt A):111145. PubMed ID: 37935092
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
Zhu H; Blum RH; Bernareggi D; Ask EH; Wu Z; Hoel HJ; Meng Z; Wu C; Guan KL; Malmberg KJ; Kaufman DS
Cell Stem Cell; 2020 Aug; 27(2):224-237.e6. PubMed ID: 32531207
[TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Hadfield MJ; Safran H; Purbhoo MA; Grossman JE; Buell JS; Carneiro BA
Oncogene; 2024 Mar; 43(10):758-762. PubMed ID: 38281989
[TBL] [Abstract][Full Text] [Related]
20. The Role of Checkpoint Inhibitors in Autoimmune Diseases: Similarities and Differences Compared with Cancer.
Kaur K; Chen PC; Ko MW; Jewett A
Crit Rev Immunol; 2022; 42(3):23-36. PubMed ID: 37017624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
